Stockscreener 앱 받기
50.56
0.08%
-0.04
시장 영업 전:
50.93
0.37
+0.73%
전일 마감가:
$50.60
열려 있는:
$51.59
하루 거래량:
6.23M
Relative Volume:
2.35
시가총액:
$123.48B
수익:
$48.03B
순이익/손실:
$6.06B
주가수익비율:
20.24
EPS:
2.4983
순현금흐름:
$9.91B
1주 성능:
-1.27%
1개월 성능:
-12.45%
6개월 성능:
-7.13%
1년 성능:
+10.39%
1일 변동 폭
$50.39
$51.62
1주일 범위
$48.72
$52.22
52주 변동 폭
$45.22
$60.12
사노피 ADR Stock (SNY) Company Profile
SNY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
50.56 | 123.48B | 48.03B | 6.06B | 9.91B | 2.4983 |
|
LLY
Lilly Eli Co
|
734.90 | 660.07B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
153.91 | 344.63B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
171.68 | 303.70B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
62.88 | 279.13B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
109.58 | 216.43B | 51.72B | 11.94B | 13.81B | 5.88 |
사노피 ADR Stock (SNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-03-21 | 개시 | Goldman | Neutral |
| 2025-01-30 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-07-26 | 재확인 | Argus | Buy |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2023-12-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-10-30 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-09-06 | 업그레이드 | Berenberg | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-28 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-03-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-12-13 | 재개 | Morgan Stanley | Overweight |
| 2022-08-12 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-08-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-09-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | 개시 | Deutsche Bank | Sell |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-03-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-03-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-02-11 | 개시 | SVB Leerink | Mkt Perform |
| 2020-01-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-09-20 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | 개시 | Bernstein | Outperform |
| 2019-08-14 | 업그레이드 | UBS | Neutral → Buy |
| 2018-12-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-11-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-09-10 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-03-23 | 업그레이드 | Liberum | Hold → Buy |
| 2018-01-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2017-12-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2017-08-30 | 업그레이드 | HSBC Securities | Reduce → Hold |
모두보기
사노피 ADR 주식(SNY)의 최신 뉴스
Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study - Benzinga
Futu Holdings ADR Clears Key Benchmark, Hitting 90-Plus RS Rating - inkl
European Equities Traded in the US as ADRs Fall in Tuesday Trading - MSN
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
Radian Group Clears Key Benchmark, Hitting 80-Plus RS Rating - inkl
Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now? - Yahoo Finance
Led by Dupixent, Solid Immunology Position Helps Support Steady Long-Term Growth for Sanofi - Morningstar
4 healthcare stocks attractive on valuation and ESG risk - Morningstar
Can you achieve global diversification with multinational companies? - Morningstar
Best international companies to own: 2023 Edition - Morningstar
SNY Quantitative Stock Analysis - Nasdaq
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Top 3 International Names Offering High-Dividend Yields - TheStreet Pro
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView
Know Labs Inc (KNW) Stock: A Closer Look at the Market Potential - The News Heater
Piper Sandler Shows Market Leadership With Jump To 83 RS Rating - Inkl
Sanofi ADR Shows Market Leadership With Jump To 82 RS Rating - Investor's Business Daily
Gold Field ADR Sees Its Composite Rating Rise To 99 - Inkl
ZEEKR Intelligent ADR Shows Rising Price Performance With Jump To 80 RS Rating - Inkl
Validea Detailed Fundamental AnalysisSNY - Nasdaq
Harrow Earns Relative Strength Rating Upgrade - Inkl
Sanofi ADR Earns RS Rating Upgrade - Investor's Business Daily
Newmont Earns RS Rating Upgrade - Inkl
What was Skechers U S A, Inc (SKX)’s performance in the last session? - US Post News
Sanofi ADR (SNY) requires closer examination - US Post News
Sanofi ADR (SNY): A Technical Analysis - The News Heater
GNPX’s Market Whiplash: -38.94% YTD Decline, -42.28% Plunge in 30 Days - The InvestChronicle
Applied Materials Inc’s Banking’s 100-Day Moving Average at 182.60: Will the Stock Break Through? - The InvestChronicle
ESPR’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend - Investor's Business Daily
Waltham biotech plans to raise $150M in IPO this week - The Business Journals
사노피 ADR (SNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.78%
자본화:
|
볼륨(24시간):